Aescap Venture

Type

Private equity

Status

Active

Location

Amsterdam, Netherlands

Total investments

29

Average round size

21M

Portfolio companies

12

Rounds per year

1.53

Lead investments

7

Follow on index

0.59

Exits

6

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth DiagnosticsGeneticsMedicalPharmaceuticalTherapeuticsRenewable EnergyChemicalBiopharmaClinical Trials

Summary

Aescap Venture appeared to be the VC, which was created in 2005. The venture was found in Europe in The Netherlands. The leading representative office of defined VC is situated in the Amsterdam.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Aescap Venture, startups are often financed by Sunstone Life Science Ventures, Novo Holdings, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are TVM Capital, Sunstone Life Science Ventures, De Hoge Dennen Capital. In the next rounds fund is usually obtained by Johnson & Johnson Development Corporation, Wellcome Trust, TVM Capital.

The overall number of key employees were 2.

The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Chemical, Health Care. Among the most popular portfolio startups of the fund, we may highlight ProtAffin Biotechnologie, Aquapharm Biodiscovery, EOS (Ethical Oncology Science).

The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2010. Opposing the other organizations, this Aescap Venture works on 6 percentage points less the average amount of lead investments. Speaking about the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year. The increased amount of exits for fund were in 2015.

Show more

Investor highlights

Industry focus
Biotech/Life Sciences
Geo focus
AlbaniaAndorraAustriaBelgiumBosnia and Herzegovina Show 40 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
29
Lead investments
7
Exits
6
Rounds per year
1.53
Follow on index
0.59
Investments by industry
  • Biotechnology (29)
  • Pharmaceutical (17)
  • Biopharma (11)
  • Health Diagnostics (10)
  • Therapeutics (6)
  • Show 8 more
Investments by region
  • Denmark (5)
  • Netherlands (5)
  • Switzerland (3)
  • United Kingdom (7)
  • Belgium (2)
  • Show 4 more
Peak activity year
2010

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
17
Avg. valuation at time of investment
49M
Group Appearance index
0.90
Avg. company exit year
10
Avg. multiplicator
0.90
Strategy success index
0.20

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Aquapharm Biodiscovery 05 Apr 2010 Biotechnology, Pharmaceutical, Chemical Late Stage Venture 6M England, United Kingdom, United Kingdom
Biocartis 15 Oct 2009 Biotechnology, Health Diagnostics, Medical Device Early Stage Venture 11M Switzerland, Vaud, Lausanne
Sualab 01 Jun 2016 Software, Artificial Intelligence, Computer Early Stage Venture 870K Seoul, Seoul-t'ukpyolsi, South Korea

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.